The cell and gene therapy (CGT) space continues to make headlines and stand out as a beacon of innovation and opportunity, attracting considerable attention from investors and biotech developers. Reports consistently underscore the industry's potential, with its robust growth trajectory remaining resilient even amidst broader investment downturns. In 2023 alone, investments totaled $11.7bn.
Key Considerations When Acquiring A Cell And Gene Biotech
Insights From Project Farma
Stakeholders looking to gain deeper insights into potential cell and gene therapy candidates and optimize R&D strategies can employ several strategies to inform portfolio management decisions.
